Neurobiological mechanisms of pain in sickle cell disease.
Pain is a frequent complaint of people living with sickle cell disease (SCD); however, the neurobiology of pain in SCD remains poorly understood. Whereas this pain has been thought to be primarily related to visceral and somatic tissue injury subsequent to vaso-occlusion events, emerging evidence from human and animal studies has suggested that a component of SCD pain may be related to neuropathic processes. Significant knowledge has been obtained from studies of molecular and neurobiological mechanisms leading to and maintaining neuropathic pain. Some of the most promising evidence has implicated major roles of protein kinase C and Ca2+/calmodulin-dependent protein kinase II, and their interaction with the N-methyl-D-aspartate receptors and the transient receptor potential vanilloid 1 receptor in the development of neuropathic pain. The latest evidence from our studies suggests that these pathways are important for SCD pain as well. Coupled with emerging animal models of SCD pain, we can now start to elucidate neurobiological mechanisms underlying pain in SCD, which may lead to better understanding and effective therapies.
Department of Biopharmaceutical Sciences, College of Pharmacy, Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA. zjwang@uic.edu
Zaijie J
ZJ
Wang
Diana J
DJ
Wilkie
Robert
R
Molokie
D000755:Anemia, Sickle Cell / Q000150:complications* / Q000503:physiopathology; D000818:Animals; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000378:metabolism; D006801:Humans; D009424:Nervous System Physiological Phenomena; D009437:Neuralgia / Q000201:enzymology / Q000209:etiology* / Q000503:physiopathology*; D009619:Nociceptors / Q000378:metabolism
D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2
J Neurosci. 2010 Jan 6;30(1):38-46
20053885
Pathol Biol (Paris). 2000 Sep;48(7):648-57
11072643
Neuroreport. 2000 Jan 17;11(1):49-55
10683828
Pain. 1995 Sep;62(3):259-274
8657426
Neuropsychopharmacology. 1995 Dec;13(4):347-56
8747759
Eur J Neurosci. 2005 May;21(9):2467-74
15932604
Curr Opin Hematol. 1997 Mar;4(2):88-93
9107524
Anesth Analg. 2007 Dec;105(6):1650-6, table of contents
18042863
J Pharmacol Exp Ther. 2009 Aug;330(2):650-9
19478130
J Pain. 2009 Sep;10(9):895-926
19712899
Science. 1997 Oct 10;278(5336):279-83
9323205
Yale J Biol Med. 2001 May-Jun;74(3):179-84
11501714
Life Sci. 2006 Sep 27;79(18):1681-91
16831450
Front Neurosci. 2009 Sep 15;3(2):175-81
20011139
Exp Neurol. 2009 Feb;215(2):298-307
19046970
Brain Res Mol Brain Res. 2000 Dec 28;85(1-2):239-50
11146127
Annu Rev Neurosci. 2009;32:1-32
19400724
Neuroscience. 2004;128(4):889-98
15464294
J Pharmacol Exp Ther. 2008 Apr;325(1):267-75
18178903
Br J Haematol. 2001 Jan;112(1):19-25
11167777
Science. 1997 Oct 31;278(5339):873-6
9346487
Biochem J. 2004 Feb 15;378(Pt 1):1-16
14653781
Brain Res. 2002 Aug 30;947(2):252-9
12176168
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12155-9
1465455
J Natl Med Assoc. 2010 Jan;102(1):18-27
20158132
Nouv Rev Fr Hematol. 1990;32(6):407-8
2101873
Curr Pharm Des. 2002;8(3):177-200
11812267
Pain. 2005 Oct;117(3):259-270
16150547
Cell. 2009 Oct 16;139(2):267-84
19837031
Br J Haematol. 2008 Jan;140(1):80-5
17991298
J Neurosci. 2002 May 15;22(10):4196-204
12019337
Acad Emerg Med. 2004 Sep;11(9):968-72
15347549
Ann Intern Med. 2008 Jan 15;148(2):94-101
18195334
Am J Hematol. 2005 May;79(1):17-25
15849770
Nat Rev Neurosci. 2009 Jan;10(1):23-36
19096368
N Engl J Med. 1991 Jul 4;325(1):11-6
1710777
J Neurophysiol. 1999 Mar;81(3):1104-12
10085337
Adv Drug Deliv Rev. 2003 Aug 28;55(8):949-65
12935939
Blood. 2006 Feb 15;107(4):1651-8
16166585
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6061-5
17389363
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14886-90
9843985
Neuron. 1992 Jan;8(1):3-11
1370373
Neurosci Lett. 2005 Dec 2;389(2):94-8
16095822
Science. 1997 Oct 31;278(5339):876-8
9346488
J Neurochem. 2002 Jul;82(2):316-28
12124432